Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Cash from Operations (2016 - 2025)

Aptevo Therapeutics' Cash from Operations history spans 11 years, with the latest figure at 6656000.0 for Q3 2025.

  • For Q3 2025, Cash from Operations fell 28.0% year-over-year to 6656000.0; the TTM value through Sep 2025 reached 26141000.0, down 12.42%, while the annual FY2024 figure was 23785000.0, 102.77% down from the prior year.
  • Cash from Operations for Q3 2025 was 6656000.0 at Aptevo Therapeutics, up from 7100000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 4566000.0 in Q1 2023 and bottomed at 7504000.0 in Q1 2021.
  • The 5-year median for Cash from Operations is 5785000.0 (2024), against an average of 5188000.0.
  • The largest annual shift saw Cash from Operations surged 189.23% in 2023 before it crashed 246.74% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 3880000.0 in 2021, then plummeted by 53.07% to 5939000.0 in 2022, then rose by 11.55% to 5253000.0 in 2023, then fell by 10.13% to 5785000.0 in 2024, then decreased by 15.06% to 6656000.0 in 2025.
  • Per Business Quant, the three most recent readings for APVO's Cash from Operations are 6656000.0 (Q3 2025), 7100000.0 (Q2 2025), and 6600000.0 (Q1 2025).